Trexquant Investment LP Buys New Holdings in United Therapeutics Corporation $UTHR

Key Points

• Trexquant Investment LP has acquired a new position in United Therapeutics Corporation, purchasing 8,919 shares valued at approximately $2.75 million during the first quarter.
• United Therapeutics has experienced recent insider activity, with several executives selling shares, including CFO James Edgemond who sold 12,000 shares valued at nearly $3.9 million.
• The company's stock is currently rated as a "Moderate Buy" by analysts, who have set an average price target of $412.69 after various adjustments from major firms.

Trexquant Investment LP bought a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,919 shares of the biotechnology company's stock, valued at approximately $2,749,000.

Several other institutional investors have also recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in United Therapeutics during the 1st quarter valued at about $313,000. Allianz Asset Management GmbH lifted its holdings in United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after buying an additional 33,254 shares in the last quarter. LPL Financial LLC lifted its holdings in United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after buying an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after buying an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in United Therapeutics during the 1st quarter valued at about $227,000. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research analyst reports. Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Morgan Stanley reduced their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a report on Thursday, August 14th. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $429.62.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $14,168,409.01. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 118,181 shares of company stock valued at $39,441,679 in the last three months. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of UTHR traded up $20.05 during trading hours on Friday, hitting $400.52. The stock had a trading volume of 924,693 shares, compared to its average volume of 848,265. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The firm has a market capitalization of $18.07 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 6.08 and a beta of 0.62. The firm has a 50-day moving average price of $307.69 and a 200 day moving average price of $305.80.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same period in the previous year, the company earned $5.85 EPS. United Therapeutics's quarterly revenue was up 11.7% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.